GO
Loading...

Pharmaceuticals

More

  • It is standing room only here at the advisory panel meeting on GlaxoSmithKline's Avandia. I count about 300 people in the main ballroom and about 50 more watching on closed circuit in an overflow breakout room. The place is crawling with PR people, especially from Glaxo which like most drug companies at the center of a storm like this one has set up a war room here.

  • Earnings reports and corporate announcements were some of the catalysts behind the most actively traded stocks on Monday.

  • DNDN's Provenge And GSK's Avandia: In FDA Spotlight Monday, 30 Jul 2007 | 10:50 AM ET

    As a big FDA Advisory Committee meeting is taking place here in Gaithersburg, Maryland on the safety of GlaxoSmithKline's Avandia, the head of the agency has been named in a separate lawsuit. A non-profit group calling itself "CareToLive" is suing FDA Commissioner Dr. Andrew von Eschenbach over the recent delay in the potential approval of Dendreon's Provenge.

  • M&A news and stock buybacks were some of the catalysts behind the most actively traded stocks on Friday.

  • Sepracor  posted lower-than-expected results Friday and cut its 2007 outlook amid competition for its insomnia drug and reduced reimbursement for its asthma drug, sending its shares down 20 percent.

  • Glaxo Signs $1.5 Billion Drug Deal with Targacept Friday, 27 Jul 2007 | 10:41 AM ET

    GlaxoSmithKline took a further step to boost its new drug pipeline on Friday by clinching a drug development deal potentially worth more than $1.5 billion with U.S. biotech firm Targacept.

  • AstraZeneca plans to axe around 7,600 jobs as part of an expanded cost-cutting drive, it said on Thursday as it nudged up its 2007 earnings outlook.

  • Bristol-Myers Profit Rises on Newer Drugs Thursday, 26 Jul 2007 | 11:42 AM ET

    Bristol-Myers Squibb Thursday said quarterly earnings rose 6 percent on resumed growth for its Plavix blood-clot preventer, and higher sales of newer drugs that offset waning demand for older products.

  • I think I just killed a tree. This morning I printed out the GlaxoSmithKline and FDA documents that were posted on the agency's Web site ahead of the advisory committee meeting on Avandia safety next Monday. About 700 pages! Nearly as many pages as the new "Harry Potter" book, but not nearly as entertaining.

  • Glaxo Says New Study Shows No Avandia Heart Risk Thursday, 26 Jul 2007 | 9:03 AM ET

    A new study of health insurance records of more than 400,000 U.S. diabetics found no higher risk of heart attacks with GlaxoSmithKline Plc's pill Avandia when compared with other oral diabetes drugs, the drugmaker said in documents made public Thursday.

  • UCB Profit Fell 39% in First Half Thursday, 26 Jul 2007 | 7:15 AM ET

    Belgian drug maker UCB Group said Thursday first-half net profit fell 39% as it absorbed the cost of taking over Germany's Schwarz Pharm.

  • Stop Trading! Wednesday, 25 Jul 2007 | 5:08 PM ET

    Want to know the best banks to buy? Cramer has the answer.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Quarterly earnings reports and new drug trial data were some of the catalysts behind the most actively traded stocks on Wednesday.

  • Glaxo's $25 Billion Stock "Prescription" Remedy Wednesday, 25 Jul 2007 | 11:56 AM ET

    GlaxoSmithKline is rallying today after reporting that second quarter sales of its diabetes drug Avandia, fell 31% in the U.S. from the same time a year ago. And from the first quarter of this year to the second quarter, revenue in the U.S. from the blockbuster pill slid $120 million. So, why are investors buying the beaten-down stock?

  • Glaxo Doubles Buyback to $25 Billion as Earnings Flatten Wednesday, 25 Jul 2007 | 10:57 AM ET

    GlaxoSmithKline more than doubled its share buyback programme to 12 billion pounds ($25billion) on Wednesday, boosting its shares even as sliding sales of diabetes drug Avandia held back second-quarter profit.

  • Merck Net Profit Tops Target Wednesday, 25 Jul 2007 | 3:43 AM ET

    Merck said second-quarter net profit slumped to 85.5 million euros ($117.9 million) from 528.5 million euros in the year-earlier period after a gain from the sale of assets last year was not repeated and as the company wrote down the value of some inventory after buying Serono.

  • With little or no fanfare Pfizer launched a new ad campaign for its erectile dysfunction drug Viagra on NBC Nightly News last night. Pfizer has gotten into a bit of trouble before for its relatively racy Viagra spots like the "Horny Devil" campaign featuring the guy with two horns growing out of his head. This time it's got a bunch of 40-something guys sitting around a dusty barn singing "Viva Viagra" to the tune of Elvis' "Viva Las Vegas".

  • Quarterly earnings reports and corporate alliances were some of the catalysts behind the most actively traded stocks on Tuesday.

  • FDA Seeks More Data on Wyeth Menopause Drug Tuesday, 24 Jul 2007 | 10:16 AM ET

    The FDA is seeking a one-year study of how the drug Pristiq affects the heart and liver, said Wyeth's chief medical officer, Dr. Gary Stiles.

  • CNBC's Domm: Today's Agenda in the Markets Tuesday, 24 Jul 2007 | 8:53 AM ET

    Wall Street is heading for a lower opening as some weak earnings and credit market jitters outweigh positive profit reports from companies like Pepsico and Lockheed-Martin. European markets are moving lower after overnight gains in Tokyo and Hong Kong shares.